Saskia Biskup co-founded CeGaT GmbH in 2009. As a Human Geneticist, Research Scientist, and physian, she positions herself at the interface of diagnostics, research, and clinic.

She gathered international experience at the Johns Hopkins University in Baltimore, MD, USA. Her research at that time revolved around LRRK2, a gene involved in Parkinson’s disease, and the development of new biomarkers to enable early prediction of neurodegenerative diseases. Saskia Biskup was among the first to discover variations in the LRRK2 gene; LRRK2 is the gene which is worldwide associated with Parkinson’s Disease (Neuron 2004). She was awarded multiple international prizes for her research.

In 2010, Saskia Biskup founded the Praxis für Humangenetik, now Zentrum für Humangenetik Tübingen (Center for Human Genetics), where she sees patients daily. Her central mission is to offer patients diagnostics that incorporate the latest scientific breakthroughs to find the genetic cause of disease. An important aspect of her work centers on characterizing cancer cells, as the identification of specific genetic changes can enable targeted treatment and the development of vaccines that empower the immune system to fight cancer cells. This resonates with the rapidly advancing field of precision medicine, where personalized treatments are developed based on accurate diagnoses and an understanding of the individual’s disease.

Biskup and her team are actively contributing to research in the field of human genetics. Together with partners, they publish about 20 scientific articles per year with a current focus on oncology. Furthermore, the achievements of CeGaT GmbH, coupled with its innovative technology platforms, have facilitated the establishment of additional subsidiary ventures, particularly in the domains of prenatal diagnostics and personalized tumor vaccines.